Investigation of a Cluster of Extensively Drug Resistant Shigellosis Associated with a Cruise Ship

ICR 202003-0920-004

OMB: 0920-1288

Federal Form Document

Forms and Documents
Document
Name
Status
Form and Instruction
New
Form and Instruction
New
Form and Instruction
New
Supplementary Document
2020-03-17
Supplementary Document
2020-03-17
Supporting Statement A
2020-03-17
Supporting Statement B
2020-03-16
Supplementary Document
2020-03-16
Supplementary Document
2020-03-16
Supplementary Document
2020-03-16
ICR Details
0920-1288 202003-0920-004
Historical Active
HHS/CDC 0920-20LI
Investigation of a Cluster of Extensively Drug Resistant Shigellosis Associated with a Cruise Ship
New collection (Request for a new OMB Control Number)   No
Emergency 03/17/2020
Approved with change 03/17/2020
Retrieve Notice of Action (NOA) 03/17/2020
Approved consistent with the understanding the CDC will work with its desk officer to determine the appropriate pathway forward should the agency want to revise or extend this collection. The OMB control number, expiration date, and PRA statement will be clearly displayed on all materials.
  Inventory as of this Action Requested Previously Approved
06/30/2020 3 Months From Approved
4,217 0 0
704 0 0
0 0 0

On February 13, 2020 CDC was notified by Australian public health authorities of three cases of infection with extensively drug-resistant (XDR) Shigella associated with Cruise X. On February 20, 2020, CDC notified state and local enteric disease epidemiologists of these cases, and asked states to notify CDC of any patients with Shigella infection who reported taking a cruise matching the characteristics of Cruise X. As a result of preliminary case finding, a total of 9 U.S. cases were identified as associated with Cruise X. This investigation is submitted to identify additional cases and better characterize cases of acute gastroenteritis (AGE) and shigellosis associated with Cruise X. This will inform strategies to prevent introduction and transmission of XDR Shigella within the United States, and to identify future prevention strategies.
CDC cannot reasonably comply with the normal clearance because the initial investigation suggests it is critical to rapidly begin collection of patient data from multiple states in order to identify individuals with infections and prevent transmission of this highly resistant organism within the U.S. Because the collection of patient data is projected to begin on March 13, 2020, accelerated OMB review is requested.

US Code: 42 USC 231 Name of Law: U.S. PHSA
  
None

Not associated with rulemaking

No

  Total Approved Previously Approved Change Due to New Statute Change Due to Agency Discretion Change Due to Adjustment in Estimate Change Due to Potential Violation of the PRA
Annual Number of Responses 4,217 0 0 4,217 0 0
Annual Time Burden (Hours) 704 0 0 704 0 0
Annual Cost Burden (Dollars) 0 0 0 0 0 0
Yes
Miscellaneous Actions
No
Submission is a New Emergency ICR

$12,742
No
    Yes
    No
No
No
No
Uncollected
Jeffrey Zirger 404 639-7118 wtj5@cdc.gov

  No

On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
 
 
 
 
 
 
 
    (i) Why the information is being collected;
    (ii) Use of information;
    (iii) Burden estimate;
    (iv) Nature of response (voluntary, required for a benefit, or mandatory);
    (v) Nature and extent of confidentiality; and
    (vi) Need to display currently valid OMB control number;
 
 
 
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.
03/17/2020


© 2024 OMB.report | Privacy Policy